scorecardresearch
Thursday, April 25, 2024
Support Our Journalism
HomeHealthIsraeli hospital claims it has developed a Covid 'cure', drug trial shows...

Israeli hospital claims it has developed a Covid ‘cure’, drug trial shows 96% positive result

Researchers at Ichilov Hospital in Tel Aviv said the drug EXO-CD24, which was being developed to treat cancer, resulted in 29 of 30 trial patients recovering from Covid.

Follow Us :
Text Size:

New Delhi: Researchers from an Israeli hospital claim to have developed a drug that can “cure” Covid-19.

According to doctors at the Ichilov Hospital in Tel Aviv, the preliminary trial results of the drug yielded a 96 per cent positive result on Covid patients.

Called EXO-CD24, it is a targeted drug that was being developed as a cure for cancer for the past few years.

Professor Nadir Arber from Ichilov Hospital’s Integrated Cancer Prevention Center, who has also been part of the drug’s development, said that the hospital had tested the medication on Covid-19 patients in serious and moderate condition.

Out of the 30 patients who were administered EXO-CD24, 29 showed an improvement in two days and were discharged from the hospital within three to five days. One patient took longer to recover.

In light of the positive trial results, the hospital has reached out to Israel health ministry requesting them to extend the trial.


Also read: India’s R value remains steady at 0.92 this week, but many states see a rise in infection rate


Another possible Covid ‘cure’

Apart from the Ichilov Hospital, the Hadassah Medical Center in Jerusalem has also reported a drug that could be a potential cure for Covid-19.

The drug Allocetra, developed by the Israeli immunotherapy company Enlivex Therapeutics, was tested on 16 severe and critical Covid-19 patients.

These patients survived a 28-day phase 2 clinical trial period. The drug attempts to treat the ‘over-response’ of immune system, called a cytokine storm, which is commonly seen in Covid-19 patients requiring critical care.

Out of the 16 patients who were given the treatment, two critical care patients were still in intensive care at the end of the trial. Fourteen other patients recovered successfully and were discharged at the end of the trial.

The average duration of hospitalisation after receiving Allocetra was reported to be 5.3 days.


Also read: Pfizer withdraws application for emergency use of its Covid vaccine in India


 

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

2 COMMENTS

  1. Let’s get this right. It has a 96% survival rate on a disease that currently in the USA, witch shows the most cases has a 98.5% survival rate?? Seems my odds are better with out taking it.

  2. Hop the Govt and drug regulators take note. Another combination, with a de -worming medicine and some other drug has also shown promising results. We should also carry out testing of the these in our country. It is not known when a mutation, immune to the existing vaccines will emerge. These drugs may be the only hope then, till new vaccines are developed.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular